Abbott ABT Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| Diagnostic Products | $8.94B-4.3% | $9.34B-6.5% | $9.99B-39.4% | $16.47B+6.1% | |
| Established Pharmaceuticals | $5.54B+6.6% | $5.19B+2.5% | $5.07B+3.1% | $4.91B+4.1% | |
| Medical Devices | $21.39B+12.6% | $18.99B+12.4% | $16.89B+14.1% | $14.8B+2.2% | |
| Nutritional Products | $8.45B+0.5% | $8.41B+3.2% | $8.15B+9.3% | $7.46B-10.1% | |
| Total Assets by Business | |||||
| Diagnostic Products | $32.49B— | —— | —— | —— | |
| Established Pharmaceuticals | $14.45B— | —— | —— | —— | |
| Medical Devices | $41.85B— | —— | —— | —— | |
| Nutritional Products | $19.23B— | —— | —— | —— | |
| Operating Earnings by Business | |||||
| Diagnostic Products | $1.74B-16.1% | $2.07B-14.8% | $2.43B-63.4% | $6.64B+6.5% | |
| Established Pharmaceuticals | $1.29B+4.6% | $1.23B+2.2% | $1.21B+15.0% | $1.05B+18.0% | |
| Medical Devices | $7.21B+17.2% | $6.15B+16.0% | $5.31B+19.6% | $4.44B-2.1% | |
| Nutritional Products | $1.56B+3.5% | $1.51B+12.9% | $1.33B+88.8% | $706M-60.0% | |
| Selling, general, and administrative by Business | |||||
| Diagnostic Products | $1.61B-0.4% | $1.62B+1.5% | $1.59B-9.7% | $1.77B— | |
| Established Pharmaceuticals | $1.46B+8.5% | $1.34B+0.8% | $1.33B-3.1% | $1.37B— | |
| Medical Devices | $5.45B+11.7% | $4.88B+10.5% | $4.42B+8.5% | $4.07B— | |
| Nutritional Products | $2.11B-2.6% | $2.17B+2.1% | $2.12B-5.6% | $2.25B— | |
| Cost of products sold, excluding amortization of intangible assets by Business | |||||
| Diagnostic Products | -$4.98B+0.2% | -$5B+5.1% | -$5.26B+27.8% | -$7.29B— | |
| Established Pharmaceuticals | -$2.62B-7.0% | -$2.44B-3.7% | -$2.36B-2.3% | -$2.31B— | |
| Medical Devices | -$6.97B-8.8% | -$6.41B-10.4% | -$5.8B-16.8% | -$4.97B— | |
| Nutritional Products | -$4.57B-0.8% | -$4.53B-0.8% | -$4.5B-4.2% | -$4.31B— | |
| R&D by Business | |||||
| Diagnostic Products | $602M-8.2% | $656M-6.0% | $698M-10.2% | $777M— | |
| Established Pharmaceuticals | $176M0.0% | $176M+1.7% | $173M-7.0% | $186M— | |
| Medical Devices | $1.75B+13.4% | $1.55B+13.5% | $1.36B+2.6% | $1.33B— | |
| Nutritional Products | $213M+1.9% | $209M+2.5% | $204M+6.8% | $191M— | |
| Additions to Property and Equipment by Business | |||||
| Diagnostic Products | $761M+0.4% | $758M+1.1% | $750M-9.9% | $832M-15.1% | |
| Established Pharmaceuticals | $169M-7.7% | $183M-1.1% | $185M+5.7% | $175M+3.6% | |
| Medical Devices | $658M+4.4% | $630M+4.3% | $604M+80.3% | $335M-3.7% | |
| Nutritional Products | $302M-20.9% | $382M-16.4% | $457M+82.1% | $251M+44.3% | |
| Remaining performance obligations by Business | |||||
| Diagnostic Products | $23.7B+17.9% | $20.1B+18.9% | $16.9B+8.3% | $15.6B0.0% | |
| Medical Devices | $1.73B-8.7% | $1.89B+1.9% | $1.86B+7.5% | $1.73B+2.1% | |
| Depreciation by Business | |||||
| Diagnostic Products | $533M+2.3% | $521M+4.4% | $499M+1.0% | $494M-35.0% | |
| Established Pharmaceuticals | $101M+5.2% | $96M-7.7% | $104M+7.2% | $97M+3.2% | |
| Medical Devices | $378M+10.2% | $343M+8.9% | $315M+1.3% | $311M+9.1% | |
| Nutritional Products | $175M+10.1% | $159M+2.6% | $155M0.0% | $155M+2.6% | |
| Goodwill, non-deductible by Business | |||||
| Diagnostic Products | $14.3B+1.4% | $14.1B0.0% | $14.1B-2.1% | $14.4B-4.6% | |
| Established Pharmaceuticals | $10.7B+0.9% | $10.6B-0.9% | $10.7B-0.9% | $10.8B-6.1% | |
| Medical Devices | $69B+1.9% | $67.7B+1.0% | $67B+3.7% | $64.6B-1.4% | |
| Nutritional Products | $1.14B0.0% | $1.14B-0.2% | $1.14B-0.2% | $1.14B0.0% | |
| Net Sales by Geography | |||||
| All Other Countries | $15.98B+8.1% | $14.79B+4.4% | $14.17B-5.6% | $15.01B-4.6% | |
| China | $1.91B-9.7% | $2.11B-6.2% | $2.25B+5.6% | $2.13B-10.8% | |
| Germany | $2.76B+8.7% | $2.54B+8.3% | $2.35B+0.2% | $2.34B-9.0% | |
| India | $1.87B+3.0% | $1.82B+3.8% | $1.75B+6.1% | $1.65B+5.6% | |
| International | $27.2B+6.1% | $25.63B+3.9% | $24.66B-3.3% | $25.51B-3.5% | |
| Japan | $1.48B+2.4% | $1.44B-4.8% | $1.51B-21.7% | $1.93B+14.0% | |
| Switzerland | $1.87B+7.1% | $1.75B+6.7% | $1.64B+22.6% | $1.34B+1.8% | |
| United Kingdom | $1.34B+13.1% | $1.19B+19.6% | $991M— | —— | |
| United States | $17.13B+4.9% | $16.32B+5.6% | $15.45B-14.8% | $18.14B+9.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Abbott break its business down?
- Abbott (ABT) reports net sales by business across 4 parts — Diagnostic Products, Established Pharmaceuticals, Medical Devices and Nutritional Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Abbott's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Abbott's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
